Baxter International Inc. recently launched PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.1
“PERCLOT is a strong complement to Baxter’s leading hemostat portfolio,” said Steve Wallace, president, advanced surgery at Baxter. “The launch of PERCLOT in the U.S. allows us to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for their patients.”
To coincide with the launch of PERCLOT in the U.S., Baxter is working closely with key customers representing multiple leading hospitals across the country to add PERCLOT to their standard of care for low level bleeds. PERCLOT granules have a molecular structure that rapidly absorbs water, forming a gelled adhesive matrix that provides a mechanical barrier against further bleeding and results in the accumulation of platelets, red blood cells, and coagulation proteins (thrombin, fibrinogen, etc.).
PERCLOT further enhances clinicians’ ability to optimize patient care by addressing a broader range of intraoperative bleeding. Addressing intraoperative bleeding is important in reducing blood transfusions and major complications for patients, as well as lowering the total cost of care.2,3 A blood management strategy that includes effective hemostasis is essential in today’s environment where there is a shortage of blood donations.
Baxter has successfully continued to expand the global commercial presence of PERCLOT since acquiring the product in July 2021. To date, PERCLOT has sales in more than 35 countries worldwide.
For more information on PERCLOT, visit https://advancedsurgery.baxter.com/perclot.
1 Assessment of the hemostatic efficacy of PERCLOT, Surgicel Powder, and Arista in a Porcine Liver Abrasion Model. December 2021. Baxter Date on File. REF-36820.
2 Stokes et al.: Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Services Research 2011 11:135.
3 David A. Iannitti, Chong Kim, Diane Ito & Josh Epstein (2021) Impact of an active hemostatic product treatment approach on bleeding related complications and hospital costs among inpatient surgeries in the United States, Journal of Medical Economics, 21:1,514-523, DOI: 10.1080/13696998.2021.
4 PERCLOT IFU
